Cargando…

hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway

Immunocompromised individuals are particularly vulnerable to viral infections and reactivation, especially endogenous herpes viruses such as Epstein-Barr virus (EBV), a member of oncogenic gamma-herpesviruses, which are commonly linked to pneumonia and consequently significant morbidity and mortalit...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Aiping, Wang, Xiao-juan, Fu, Jijun, Shen, Ao, Huang, Xiaotao, Chen, Zhida, Wu, Huiting, Jiang, Yu, Wang, Qian, Chen, Fei, Xiang, Andy Peng, Yu, Xiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499773/
https://www.ncbi.nlm.nih.gov/pubmed/37704783
http://dx.doi.org/10.1186/s43556-023-00137-z
_version_ 1785105779876954112
author Qin, Aiping
Wang, Xiao-juan
Fu, Jijun
Shen, Ao
Huang, Xiaotao
Chen, Zhida
Wu, Huiting
Jiang, Yu
Wang, Qian
Chen, Fei
Xiang, Andy Peng
Yu, Xiyong
author_facet Qin, Aiping
Wang, Xiao-juan
Fu, Jijun
Shen, Ao
Huang, Xiaotao
Chen, Zhida
Wu, Huiting
Jiang, Yu
Wang, Qian
Chen, Fei
Xiang, Andy Peng
Yu, Xiyong
author_sort Qin, Aiping
collection PubMed
description Immunocompromised individuals are particularly vulnerable to viral infections and reactivation, especially endogenous herpes viruses such as Epstein-Barr virus (EBV), a member of oncogenic gamma-herpesviruses, which are commonly linked to pneumonia and consequently significant morbidity and mortality. In the study of human and animal oncogenic gammaherpesviruses, the murine gamma-herpesviruses-68 (MHV-68) model has been applied, as it can induce pneumonia in immunocompromised mice. Mesenchymal stem cell (MSC) treatment has demonstrated therapeutic potential for pneumonia, as well as other forms of acute lung injury, in preclinical models. In this study, we aim to investigate the therapeutic efficacy and underlying mechanisms of human bone marrow-derived MSC (hMSC) on MHV-68-induced pneumonia. We found that intravenous administration of hMSCs significantly reduced lung damages, diminished inflammatory mediators and somehow inhibited MHV-68 replication. Furthermore, hMSCs treatment can regulate innate immune response and induce macrophage polarization from M1 to M2 phenotype, could significantly alter leukocyte infiltration and reduce pulmonary fibrosis. Our findings with co-culture system indicated that hMSCs effectively reduced the secretion of of inflammation-related factors and induced a shift in macrophage polarization, consistent with in vivo results. Further investigations revealed that hMSCs treatment suppressed the activation of macrophage ROS/NLRP3 signaling pathway in vivo and in vitro. Moreover, administration of MCC950, a selective NLRP3 inhibitor has been shown to effectively reduce ROS production and subsequently alleviate inflammation induced by MHV-68. Taken together, our work has shown that hMSCs can effectively protect mice from lethal MHV-68 pneumonia, which may throw new light on strategy for combating human EBV-associated pneumonia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43556-023-00137-z.
format Online
Article
Text
id pubmed-10499773
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-104997732023-09-15 hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway Qin, Aiping Wang, Xiao-juan Fu, Jijun Shen, Ao Huang, Xiaotao Chen, Zhida Wu, Huiting Jiang, Yu Wang, Qian Chen, Fei Xiang, Andy Peng Yu, Xiyong Mol Biomed Research Immunocompromised individuals are particularly vulnerable to viral infections and reactivation, especially endogenous herpes viruses such as Epstein-Barr virus (EBV), a member of oncogenic gamma-herpesviruses, which are commonly linked to pneumonia and consequently significant morbidity and mortality. In the study of human and animal oncogenic gammaherpesviruses, the murine gamma-herpesviruses-68 (MHV-68) model has been applied, as it can induce pneumonia in immunocompromised mice. Mesenchymal stem cell (MSC) treatment has demonstrated therapeutic potential for pneumonia, as well as other forms of acute lung injury, in preclinical models. In this study, we aim to investigate the therapeutic efficacy and underlying mechanisms of human bone marrow-derived MSC (hMSC) on MHV-68-induced pneumonia. We found that intravenous administration of hMSCs significantly reduced lung damages, diminished inflammatory mediators and somehow inhibited MHV-68 replication. Furthermore, hMSCs treatment can regulate innate immune response and induce macrophage polarization from M1 to M2 phenotype, could significantly alter leukocyte infiltration and reduce pulmonary fibrosis. Our findings with co-culture system indicated that hMSCs effectively reduced the secretion of of inflammation-related factors and induced a shift in macrophage polarization, consistent with in vivo results. Further investigations revealed that hMSCs treatment suppressed the activation of macrophage ROS/NLRP3 signaling pathway in vivo and in vitro. Moreover, administration of MCC950, a selective NLRP3 inhibitor has been shown to effectively reduce ROS production and subsequently alleviate inflammation induced by MHV-68. Taken together, our work has shown that hMSCs can effectively protect mice from lethal MHV-68 pneumonia, which may throw new light on strategy for combating human EBV-associated pneumonia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43556-023-00137-z. Springer Nature Singapore 2023-09-14 /pmc/articles/PMC10499773/ /pubmed/37704783 http://dx.doi.org/10.1186/s43556-023-00137-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Qin, Aiping
Wang, Xiao-juan
Fu, Jijun
Shen, Ao
Huang, Xiaotao
Chen, Zhida
Wu, Huiting
Jiang, Yu
Wang, Qian
Chen, Fei
Xiang, Andy Peng
Yu, Xiyong
hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway
title hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway
title_full hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway
title_fullStr hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway
title_full_unstemmed hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway
title_short hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway
title_sort hmscs treatment attenuates murine herpesvirus-68 (mhv-68) pneumonia through altering innate immune response via ros/nlrp3 signaling pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499773/
https://www.ncbi.nlm.nih.gov/pubmed/37704783
http://dx.doi.org/10.1186/s43556-023-00137-z
work_keys_str_mv AT qinaiping hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT wangxiaojuan hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT fujijun hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT shenao hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT huangxiaotao hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT chenzhida hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT wuhuiting hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT jiangyu hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT wangqian hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT chenfei hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT xiangandypeng hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway
AT yuxiyong hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway